Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Mar 26, 2026
Why Is Olaplex Holdings (OLPX) Stock Up +50% Today?

Why Is Olaplex Holdings (OLPX) Stock Up +50% Today?

Key Takeaways

  • OLPX surged approximately +50.38% in premarket trading on March 26, 2026, from a previous close of $1.33 to approximately $2.00, with an intraday premarket high of $2.03
  • The primary catalyst is a definitive acquisition agreement by German consumer goods giant Henkel AG to purchase Olaplex for $2.06 per share in an all-cash deal, valuing the company at approximately $1.4 billion
  • The transaction was unanimously approved by Olaplex's Board of Directors; controlling shareholder Advent International, which holds approximately 75% of the company, has entered into a written consent to approve the deal
  • The offer represents a ~55% premium over OLPX's March 25, 2026 closing price and a ~45% premium over the 30-day volume-weighted average price (VWAP)
  • The transaction is subject to regulatory approvals and customary closing conditions
  • Traders are watching for competing bids, regulatory clearance timelines, and any deal-close complications

Opening Summary

Olaplex Holdings, Inc. (OLPX) is a Nasdaq-listed premium hair care company known for its science-led bond-building hair repair products, widely used by professional hairstylists and retail consumers globally. In premarket trading on March 26, 2026, OLPX shares surged approximately +50.38%, moving from the previous session's closing price of $1.33 to approximately $2.00, touching an intraday premarket high of $2.03.  The explosive move was triggered by the formal announcement that German consumer goods powerhouse Henkel AG has entered into a definitive agreement to acquire 100% of Olaplex for $2.06 per share in cash, a deal totaling roughly $1.4 billion in equity value.

The Acquisition: Henkel's $1.4 Billion Deal

Henkel AG, the Düsseldorf-based manufacturer behind globally recognized brands including Schwarzkopf, Persil, and Dial, announced on March 26, 2026 that it has signed a definitive agreement to acquire all outstanding shares of Olaplex at $2.06 per share in a fully cash-funded transaction.  The deal values Olaplex at approximately $1.4 billion, representing a 55% premium over OLPX's closing price of $1.33 on March 25, 2026, and a 45% premium over the 30-day VWAP.  Henkel's stated rationale is to further expand hair care as a core category within its Consumer Brands business and to combine Olaplex's strong North American direct-to-consumer and retail footprint with Henkel's extensive global distribution reach.

Board Approval and Shareholder Backing

The transaction was unanimously approved by Olaplex's Board of Directors, providing immediate clarity on the deal's corporate legitimacy and removing execution risk at the board level.  Critically, Advent International — Olaplex's controlling shareholder with a stake of approximately 75% — has entered into a written consent committing to approve the transaction.  This majority shareholder backing effectively removes the largest potential obstacle to deal completion, as Advent's vote alone is sufficient to ratify the merger under standard shareholder approval requirements. Upon deal close, OLPX will be delisted from Nasdaq and Advent will fully exit its investment.

Olaplex's Turnaround Backdrop

The acquisition arrives after a prolonged and severe decline in OLPX shares, which had lost approximately 95% of their value since the company's September 2021 IPO at $25 per share.  In early March 2026, Olaplex reported Q4 2025 revenues of $105.12 million but posted a net loss of $13.1 million, while its full-year 2026 guidance of $414–$435 million in net sales disappointed analysts who had expected a stronger midpoint.  That earnings report triggered a sharp single-day decline to $1.47 on March 5, 2026, making the company an increasingly attractive distressed-asset target with a recognizable, premium brand still commanding meaningful consumer loyalty.

Market Context and Trading Activity

The premarket volume in OLPX is significantly elevated relative to its average daily activity of roughly 783,000 shares, consistent with a formal M&A announcement that forces the stock to reprice toward the offer value almost instantaneously.  In typical acquisition-driven moves of this nature, trading clusters just below the announced deal price as market participants account for deal completion risk, regulatory timelines, and the time value of money over the holding period — which explains why the stock is trading near $2.00–$2.03 rather than the full $2.06 offer price.  Prior to the deal announcement, OLPX had a short interest of approximately 4.81% of float with around 7.18 days to cover, adding a modest short-squeeze component to the upward price pressure as short sellers rush to close positions.

Trending AI Robots

For traders looking to navigate acquisition-driven volatility and identify the next high-probability opportunities, Tickeron's Trending AI Robots page offers a curated selection of the platform's top-performing automated trading bots. Tickeron operates hundreds of AI-powered bots covering thousands of tickers, but only those demonstrating the strongest performance under current market conditions earn a featured spot in this section. Each bot varies by strategy type, trading timeframe, risk parameters, and the symbols it covers — giving traders and investors a range of options suited to different styles and goals. Whether you're focused on momentum plays, mean-reversion strategies, or event-driven setups, exploring the Trending AI Robots section is a practical starting point for discovering tools aligned with today's market environment.

What Comes Next for OLPX

With a definitive agreement in place and majority shareholder consent secured, the primary pending milestone for OLPX is regulatory clearance from relevant antitrust and competition authorities in the U.S. and potentially Europe, given Henkel's status as a major international consumer goods conglomerate.  Traders holding OLPX at or near current premarket levels will closely monitor the deal closing timeline, any potential for a competing topping bid from a rival acquirer, and whether any regulatory complications emerge that could delay or jeopardize the transaction.  Management's ongoing execution of the broader 2026 marketing strategy remains operationally relevant until close, as continued business performance factors into the overall acquisition narrative.  Absent a competing offer or regulatory block, OLPX shares are expected to trade in a narrow range near but below the $2.06 offer price until the transaction is finalized.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitation

Related Ticker: OLPX

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry SpecialtyStores

Industry
N/A
Address
432 Park Avenue South
Phone
+1 310 691-0776
Employees
278
Web
https://www.olaplex.com
Interact to see
Advertisement
ALM shares are indicated down about 11% in early Tuesday trading after closing the prior session at $16.93. The move comes after a powerful multi‑month rally that took the stock from below $3 to an intraday high of $22.55 earlier in March, leaving it vulnerable to profit-taking and volatility.​
LUNR shares are indicated down about 7% in Tuesday premarket trading after closing the last regular session at $20.31. The pullback follows a powerful rally driven by strong 2026 revenue guidance of $900 million–$1 billion and upbeat analyst commentary, including price target hikes and buy ratings.
MAZE shares are trading approximately 27% lower in premarket on March 25, 2026, after the company reported its highly anticipated Phase 2 HORIZON trial topline data for lead drug candidate MZE829. The catalyst is a dual announcement: Phase 2 clinical data for MZE829 in APOL1-mediated kidney disease (AMKD) alongside Q4 and full-year 2025 financial results.
ARM shares surged approximately +10% in premarket trading on March 25, 2026, hitting $148.6 from a prior close of approximately $135. The primary catalyst is Arm's historic strategic pivot: the company announced it will begin selling its own self-developed AGI CPU chips, breaking its decades-long "IP licensing only" business model.
Shares of Enliven Therapeutics (ELVN) are surging approximately +15% in premarket trading on March 25, 2026, driven by renewed investor enthusiasm around the company's advancing clinical program for ELVN-001 in chronic myeloid leukemia (CML). The stock's prior closing price on March 24, 2026 was $31.15, placing the premarket indicated price near $35.82.
AVXL shares are down approximately 29% in premarket trading on Wednesday, March 25, 2026, falling to roughly $2.97 from the prior close of $4.19. The primary catalyst is Anavex's formal withdrawal of its marketing authorization application (MAA) for blarcamesine from the European Union, announced in the early hours of March 25, 2026.
Shares of GSAT are surging approximately +15% intraday on March 25, 2026, following a prior session close of $61.09. The primary catalyst is a fresh analyst note from Scotiabank highlighting Globalstar's direct-to-device satellite connectivity bypassing cellular towers — most notably in Mexico — reinforcing the company's next-generation infrastructure thesis.
Shares of ADMA are declining approximately 12% in Wednesday's session, extending a steep two-day selloff. The primary catalyst is a short-seller research report published by Culper Research on March 24, 2026, alleging that ADMA engaged in channel stuffing to artificially inflate revenue growth.
Honeywell International (HON) and TransDigm Group (TDG) are prominent players in the aerospace and industrials sector, benefiting from rising air travel demand, defense spending, and aftermarket services. This stock comparison evaluates their business models, recent performance, and market positioning to help traders and investors assess relative strengths in the current environment. With global aviation recovery and geopolitical tensions supporting sector tailwinds, professionals seeking exposure to aerospace growth versus diversified industrials stability will find these insights relevant for portfolio decisions and relative performance analysis.
PL shares are surging approximately +15% in Wednesday's session, trading near $35.89, pushing back toward the stock's 52-week high of $36.28 set on March 20, 2026. Primary catalyst: Continued momentum from a blockbuster Q4 fiscal 2026 earnings report delivered March 19, which sent revenue 41% higher year-over-year to $86.8 million, well above the $78 million Wall Street consensus.
ASTS shares surged approximately +11.00% in active intraday trading on March 25, 2026, moving from a prior close of $86.98 to approximately $96.55. The primary driver is a broad space sector rally fueled by renewed SpaceX IPO speculation, lifting satellite and space-related equities across the board.
FUBO shares are set to open about 12% lower in Wednesday’s premarket session after closing the prior day at roughly $12.02. The decline follows a strong multi-week rally powered by balance-sheet news, including the repurchase of $140.2 million of 2026 convertible notes and improving profitability trends.
One & One Green Technologies Inc. (YDDL) shares are indicated down about 13% in Wednesday’s premarket session after closing the prior regular session at $12.00. The stock had just surged 15.6% in the latest completed session, jumping from a prior close of $10.38 to $12.00, leaving it vulnerable to swift profit‑taking and volatility.
AVXL shares are indicated down about 33% in Wednesday’s premarket session, after closing the prior regular session at $4.19. The slide follows a recent drop triggered by a wider‑than‑expected fourth‑quarter loss and ongoing questions about the company’s late‑stage neurology pipeline.
AUGO shares are trading roughly 9% higher in Wednesday action, moving from a prior close of $66.42 to around $72.40 intraday. The stock’s advance extends a powerful year-long rally underpinned by record 2025 production, surging Adjusted EBITDA, and a recently declared cash dividend of $0.66 per share.
NAVN shares are surging approximately +25% in premarket trading on March 26, 2026, following a blockbuster earnings report released after the close of the prior session. Primary catalyst: Q4 fiscal year 2026 results delivered a significant beat — revenue of $178 million rose 35% year-over-year, surpassing analyst forecasts by nearly 10%.
OLPX surged approximately +50.38% in premarket trading on March 26, 2026, from a previous close of $1.33 to approximately $2.00, with an intraday premarket high of $2.03. The primary catalyst is a definitive acquisition agreement by German consumer goods giant Henkel AG to purchase Olaplex for $2.06 per share in an all-cash deal, valuing the company at approximately $1.4 billion.
TASK shares are down approximately -36% in premarket trading on March 26, 2026, the stock's official ex-dividend date for its special $3.65 per share cash dividend. The $3.65 special cash dividend — exceeding 25% of the stock's pre-ex-div market value — triggered a mandatory Nasdaq-prescribed price adjustment on today's open.
MLKN shares are down approximately 18.90% in premarket trading on March 26, 2026, falling to $15.70 from the prior session's close of $19.36. The primary catalyst is a double miss on both earnings and revenue in the company's fiscal Q3 2026 report released after the close on March 25.
Wave Life Sciences (WVE) shares are tumbling approximately 51% in premarket trading on March 26, 2026, from a prior close of $12.30 to approximately $6.03. The primary catalyst is the release of highly anticipated INLIGHT Phase 1 clinical data for WVE-007, the company's investigational INHBE GalNAc-siRNA obesity treatment, with results falling materially short of investor expectations.